Utilisation of Adjuvant Chemotherapy and 5-Year Survival Analysis of Prospectively Recorded Cohort Data for Older Adults Versus Younger Adults with Resected Primary Colon Cancer.


Journal

Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627

Informations de publication

Date de publication:
Sep 2020
Historique:
pubmed: 8 12 2019
medline: 27 3 2021
entrez: 8 12 2019
Statut: ppublish

Résumé

Colon cancer is predominantly a disease of older adults. Studies determining the influence of age on outcomes of colon cancer have conflicting results. We aim to determine the long-term outcomes and utilisation of adjuvant chemotherapy of older adults compared with younger adults who had had a resection of a primary colon cancer. Consecutive patients who had resection of a primary colon cancer between January 1, 2000 and December 31, 2010 were identified from a prospective database and stratified into three age groups: ≤ 69 years, 70 to 79 years, and ≥ 80 years. Age-related differences in patients, cancer, and treatment characteristics were determined by chi-square tests. Five-year overall survival and cancer-specific survival were determined by Kaplan-Meier method and by multivariable Cox regression analysis to adjust for potential confounding factors. Of 1135 included patients, 469 (41%) patients were aged ≤ 69 years, 382 (34%) were 70-79 years, and 284 (25%) were ≥ 80 years. Increasing age group predicted more comorbidity (p < 0.001), cardiac comorbidity (p < 0.001), right-sided cancers (p < 0.001), and less adjuvant chemotherapy (stage III only; p < 0.001). Increasing age group was associated with worse overall survival by stage (p < 0.001) but not cancer-specific survival by stage (p = 0.83). Adjuvant chemotherapy in patients with stage III colon cancer independently predicted improved overall survival (p < 0.001) and cancer-specific survival (p = 0.01). Compared with younger adults, older adults with colon cancer had worse survival outcomes and received less adjuvant chemotherapy.

Identifiants

pubmed: 31811472
doi: 10.1007/s12029-019-00343-5
pii: 10.1007/s12029-019-00343-5
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

988-997

Auteurs

Mohsen Shafiei (M)

Faculty of Medicine and Health, University of Sydney, Sydney, Australia. Mohsen.Shafiei@health.nsw.gov.au.
Concord Repatriation General Hospital, Concord, NSW, 2139, Australia. Mohsen.Shafiei@health.nsw.gov.au.
Concord Cancer Centre, Concord Repatriation General Hospital, Hospital Road, Concord, NSW, 2139, Australia. Mohsen.Shafiei@health.nsw.gov.au.

Philip Beale (P)

Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Concord Repatriation General Hospital, Concord, NSW, 2139, Australia.

Prunella Blinman (P)

Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Concord Repatriation General Hospital, Concord, NSW, 2139, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH